Last updated: May 18, 2026
Top libido peptides
1. PT-141 (Bremelanotide)
FDA-approved (Vyleesi) for premenopausal women with hypoactive sexual desire disorder (HSDD). 7-amino-acid melanocortin receptor agonist. Acts centrally on MC4R rather than peripherally on vasculature. Effective in both men and women though FDA-approved only for women.
2. Kisspeptin-10
Stimulates HPG axis upstream of GnRH/LH/FSH. Restores reproductive hormone production. Studied for hypogonadism and as fertility intervention.
3. CJC-1295 + Ipamorelin (indirect)
Improved GH/IGF-1 supports overall energy, well-being, and recovery — which indirectly supports sexual function.
4. Oxytocin
9-amino-acid peptide hormone. Studied for orgasmic function, social bonding, and relationship intimacy. Limited but interesting research.
Mechanisms compared
| Peptide | Mechanism | Approved |
|---|---|---|
| PT-141 | Central MC4R agonist | FDA-approved (Vyleesi for HSDD, women) |
| Kisspeptin-10 | HPG axis stimulation | Research only |
| Oxytocin | Neuropeptide modulation | FDA-approved (Pitocin for labor) |
| Sildenafil (Viagra) | PDE5 inhibitor (vascular) | FDA-approved |
PT-141 vs sildenafil/tadalafil
The mechanisms are fundamentally different:
- PDE5 inhibitors (Viagra, Cialis): Act on vascular smooth muscle to enable erection. Effective only if desire and arousal are already present.
- PT-141: Acts on central nervous system desire pathways. Effective on the desire side, not the mechanical side.
For some patients these are complementary (PT-141 + sildenafil); for others, one alone is sufficient.
PT-141 dosing
FDA-approved Vyleesi: 1.75 mg subcutaneous injection, 45 minutes before anticipated sexual activity. Max 8 doses per month.
Research-community protocols vary widely but generally use the FDA dose or somewhat lower.
Side effects
PT-141: Nausea (~40% with first dose), flushing, headache, injection-site reactions, transient blood pressure elevation, hyperpigmentation with regular use.
Kisspeptin: Generally well-tolerated; LH/testosterone elevation can affect estrogen sensitivity.
Is PT-141 approved for men?<br />
No — FDA approval (Vyleesi) is only for premenopausal women with HSDD. Off-label use in men exists and shows efficacy in clinical reports.
Can PT-141 be combined with Viagra?<br />
Different mechanisms suggest combination is theoretically additive. Not FDA-studied as a combination; not formally approved together. Cardiovascular risk increases.
Does kisspeptin help with low testosterone?<br />
Indirectly — by stimulating LH release, which stimulates testicular testosterone production. The effect requires intact testicular function.
Are these effective for postmenopausal women?<br />
Vyleesi is FDA-approved only for premenopausal women. Off-label use in postmenopausal women is studied but less established.